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Abstract
Background: Elevated fasting levels of branched chain amino acids (BCAAs: valine, isoleucine, leucine) in
venous blood are associated with a variety of metabolic impairments, including increased risk of type 2
diabetes (T2D). Fasting BCAA levels are influenced by non-dietary factors. However, it is unknown whether
fasting BCAAs can be altered through manipulation of dietary intake alone.
Objective: To test whether a specific dietary intervention, using differences in BCAA intake, alters fasting
BCAA levels independent of other factors.
Design: Five healthy male volunteers underwent 4 days of a low and 4 days of a high BCAA content dietary
intervention (ClinicalTrials.gov [NCT02110602]). All food and supplements were provided. Fasting BCAAs
were measured from venous blood samples by mass spectrometry at baseline and after each intervention.
Results: Diets were isocaloric; contained equal percentages of calories from carbohydrate, fats, and protein;
and differed from each other in BCAA content (1.590.1 vs. 14.090.6 g for valine; 4.590.9 g vs. 13.890.5 g
for isoleucine; 2.190.2 g vs. 27.191.0 g for leucine; pB0.0001 for all). Fasting valine was significantly lower
(p0.02) and fasting isoleucine and leucine were numerically lower following the low BCAA content vs. the
high BCAA content diet levels. The inter-individual response to the dietary interventions was variable and not
explained by adherence.
Conclusion: Short-term dietary manipulation of BCAA intake led to modest changes in fasting levels of
BCAAs. The approach from our pilot study can be expanded to test the metabolic implications of dietary
BCAA manipulation.
Keywords: branched chain amino acids; dietary intervention; nutritional modulation; cross-over clinical trial; metabolism;
insulin sensitivity
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E
levated fasting levels of branched chain amino
acids (BCAAs: isoleucine, leucine, and valine)
measured in venous blood have been associated
with metabolic risk factors for type 2 diabetes (T2D),
including obesity, insulin resistance, and elevated fasting
glucose (15). Among individuals matched for age, sex,
body mass index, and fasting glucose, levels of fasting
BCAAs remain an independent risk factor for T2D even
after controlling for measures of insulin resistance (6).
Furthermore, for individuals with T2D, reductions in
insulin resistance following gastric bypass surgery mirror
reductions in fasting BCAA levels (7). These findings
suggest that fasting levels of BCAAs are related to altered
glycemic metabolism in T2D. However, experimental
approaches are needed to clarify whether changes in
fasting levels of BCAA directly affect or are only markers
of metabolism in humans.
In animals, dietary manipulation of BCAAs can alter
glycemic metabolism. In obese mice, nutritional interven-
tions that increase all three BCAAs in the diet led to
increased fasting levels of all three BCAAs and promoted
insulin resistance (3). A second study that supplemented
research
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the diet of mice with only leucine observed increased
fasting levels of leucine but decreased fasting levels of
isoleucine and valine and decreased insulin resistance (8).
These studies demonstrate that, in animals, dietary manip-
ulation of BCAA intake can directly influence fasting
levels of BCAAs and that the effect on metabolism may
be dependent upon the manipulation of one or all BCAAs.
No human study to date has examined the effect of
dietary manipulation of BCAA intake on fasting levels of
BCAAs. One group has demonstrated that intravenous
infusion of amino acids (containing BCAAs and non-
BCAAs) acutely worsened insulin sensitivity (9). Yet,
this study leaves unanswered whether BCAAs or other
amino acids were responsible for changes in insulin
sensitivity and whether a more physiological manipula-
tion of BCAAs (i.e. through diet) would influence
circulating fasting levels of BCAAs. If dietary manipula-
tion of BCAAs influences fasting BCAA levels, then this
approach could be applied in future studies as a research
tool to explore the mechanisms linking fasting levels of
BCAAs to altered metabolism or as novel methods for
T2D prevention or treatment. We hypothesized that a
structured nutritional intervention, using differences in
BCAA intake, would alter fasting BCAA levels in healthy
volunteers independent of other factors.
Methods
Study participants
We recruited and enrolled five healthy, adult men, age
2040 years, into this single-center, single-blind, crossover
nutritional intervention study. This cohort size was
selected to provide 75% power to detect a difference in
fasting BCAAs at alpha0.05, assuming an effect of diet
as large or larger than that observed in prior animal
studies (3). Enrollment and completion is summarized
in Fig. 1. Exclusion criteria included chronic medical
conditions, such as T2D or hypertension, medication,
herbal, or vitamin supplement during the month prior to
enrollment, body mass index less than 20 kg/m2, change
of weight by more than five pounds during the month
prior to enrollment, use of nicotine-containing products
during the study, use of drugs of abuse, conditions caus-
ing intestinal malabsorption, and inability to adhere to a
prespecified meal plan, including standardized meals,
abstinence from alcohol, and limitation to one caffeinated
beverage per day. An initial exclusion threshold of
BMI greater than 25 kg/m2 was changed to 28 kg/m2 to
facilitate recruitment.
The protocol was approved by the local institutional
review board, and informed consent was obtained from all
study participants. The trial was registered on Clinical
Trials.gov (NCT02110602) prior to enrollment. Partici-
pants were recruited through local advertising between
March and July 2014, and all were compensated for their
study involvement.
Study protocol and laboratory measurements
Participants attended five visits at the Massachusetts
General Hospital Clinical Research Center (CRC); parti-
cipants arrived to each study visit after having fasted for
at least 8 h. At Visit 1, weight and fasting blood glucose
were measured from a venous sample and a full medical
history was obtained. A research nutritionist interviewed
each participant, calculated daily caloric requirements
using the Mifflin St. Joer equation, and cross-checked the
output with 2530 kilocalories per kilogram of partici-
pant body weight. Activity factors were based on the
results of the Paffenbarger questionnaire. This informa-
tion was used to construct the study diets with adequate
calories personalized to each participant. Between Visits
1 and 2 (an approximately 2-week period), participants
consumed their native diet and completed a 4-day food
log, which was used to estimate nutrient content of the
native diet. Food logs were not used to estimate caloric
requirements for the study diets.
At Visit 2, the 4-day food log was reviewed with
assistance from a research nutritionist. Weight and fasting
blood work for measurement of venous glucose, insulin,
and BCAAs was performed just prior to starting the first
study diet. Glucose was measured with a hexokinase assay
(Roche, Indianapolis, IN); insulin was measured using a
radio-immunoassay (Beckman Coulter, Fullerton, CA);
and BCAAs were measured using an established platform
(see Measurement of BCAAs below). After these measure-
ments were completed, participants were provided with
4 days of meals and supplements for the first study period.
Breakfast for the first study period was eaten under
observation in the CRC during Visit 2, and the remainder
of the diet was consumed outside of the CRC. Visit 3
occurred at the CRC 3 days after Visit 2. At Visit 3, weight
and fasting blood work for venous glucose, insulin, and
BCAAs was repeated to assess values after completing the
first study period. Any unfinished food or supplements
were returned, and each participant completed an anon-
ymous survey on aspects of adherence and quality of the
first study period.
The participant then began a 3-day ‘wash-out’ of
the first study period, during which he ate his native
diet. The participant returned to the CRC for Visits 4 and
5, at which the activities from Visits 2 and 3, respectively,
were repeated for the second study period.
Low and high BCAA content dietary interventions
All participants received both the low and high BCAA
content diets. Diets were provided in random order, and
participants were not told in what order the interventions
were provided. The elements of each dietary intervention
are shown in Table 1. Foods and supplements were
Nicole Landa Cavallaro et al.
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provided in take-out containers that could be stored,
refrigerated and heated, if needed, by the participants.
The total calories of each meal plan were designed to
meet the needs of each participant and assure weight
maintenance during the two study diets. As the total
caloric intake (and therefore total grams of protein)
varied for each participant, the supplement levels in each
nutritional arm were adjusted to achieve the target
percentage of total protein from BCAAs at each meal.
BCAAs are found in most protein-containing foods;
therefore, the food components of the study diet inter-
ventions were generally low in protein. To achieve a low
BCAA content intervention with an amount of protein
typical for an American diet, participants consumed
maple syrup urine disease (MSUD) Express (Vitaflo;
Alexandria, VA) with each prepared meal. This BCAA-
free amino acid supplement allowed for the food to
contain a low amount of protein from the BCAAs for the
low BCAA content diet but to have equal calories from
protein as compared with the high BCAA content diet.
The low BCAA content diet was intended to provide
approximately 1% of protein calories from valine and
isoleucine and 2% of protein calories from leucine,
mirroring the 1:2:1 ratio for valine:leucine:isoleucine
observed in a typical American diet. To achieve a high
BCAA content intervention with an amount of protein
Fig. 1. Study enrollment and completion.
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typical for an American diet, participants consumed
L-isoleucine, L-leucine, and L-valine supplements (AjiPure
BCAA, Ajinomoto; Fort Lee, NJ) with each prepared
meal. The high BCAA content diet was intended to
provide approximately 14% of protein calories from
valine and isoleucine and 28% of protein calories from
leucine, again mirroring the 1:2:1 ratio for valine:leucine:
isoleucine observed in a typical American diet.
Measurement of BCAAs
Fasting BCAAs were analyzed on a validated platform
for amino acid measurement (6); the platform also allows
for simultaneous measurements of all amino acids as well
as additional sugars, nucleic acids, and serum metabo-
lites. Plasma venous samples from all participants were
analyzed together in one batch and in random order.
Reference pooled plasma samples were analyzed with the
study samples and were placed in the analysis queue at
the initiation.
Liquid chromatography tandem mass spectrometer
(LC-MS/MS) peak areas were integrated and relative
quantitative information was used in these analyses. The
signal-to-noise ratio (S/N) of the metabolite peak area
was greater than 30 in every sample (average S/N122,
s.d.51.8), and therefore exceeded thresholds typically
used to define limits of detection (S/N3) and quantita-
tion (S/N10). All LC-MS analyses were performed
using a 4000 QTrap triple quadrupole mass spectrometer
(AB SCIEX; Foster City, CA) coupled to either an 1100 or
1200 Series pump (Agilent Technologies; Santa Clara,
CA) or an HTS PAL autosampler (Leap Technologies;
Carrboro, NC) equipped with a column heater.
Internal standard peak areas were monitored for quality
control, and individual samples with peak areas differing
from the group by more than two standard deviations
were re-analyzed. MultiQuant software (Version 1.1; AB
SCIEX; Foster City, CA) was used for automated peak
integration, and metabolite peaks were manually reviewed
for quality of integration and compared against a known
standard to confirm identity.
Statistical analysis
Analyses were conducted using GraphPad Prism (version
5.00 for Windows; San Diego, CA).
The 4-day dietary intake data were analyzed using
Nutrition Data System for Research software (version
2013, Nutrition Coordinating Center (NCC); University
of Minnesota, Minneapolis, MN). Pronutra (version 3.4.0;
Viocare; Princeton, NJ) was used to analyze the nutrient
content of the study diets. All fasting BCAA measure-
ments were log transformed to approximate a normal
distribution. Mean and standard error were provided
for all quantitative variables, and paired t-tests were used
Table 1. Elements of the controlled study diets
Low BCAA Diet High BCAA Diet
Day 1, 3 Day 2, 4 Day 1, 3 Day 2, 4
Breakfast Coffee or tea with
cream and sugar
Coffee or tea with
cream and sugar
Coffee or tea with
cream and sugar
Coffee or tea with
cream and sugar
Blueberry muffin Waffles with syrup
and butter
Blueberry muffin Waffles with syrup
and butter
Nutrigrain bar Applesauce Nutrigrain bar Applesauce
Mandarin orange sections Mandarin orange sections
Lunch Portobello, eggplant and
pepper sandwich
Vegan lasagna Portobello, eggplant and
pepper sandwich
Meat lasagna
Canned peaches Tossed salad with oil
and vinegar
Canned peaches Tossed salad with oil
and vinegar
Mixed vegetables Fresh orange Mixed vegetables Fresh orange
Graham crackers Graham crackers
Dinner Portobello burger Stuffed pepper Portobello burger
with cheese
Stuffed pepper with
cheese and kidney beans
Potato chips Mixed vegetables Potato chips Mixed vegetables
Hard candy Hershey kiss Hard candy Hershey kiss
Fresh apple Fresh apple
Supplement MSUD Express MSUD Express AjiPure BCAA AjiPure BCAA
The dietary components for each day of the low and high BCAA interventions are shown. Supplements were consumed at all meals. Meal plans were
organized for each participant, and the amount of food and supplements were based on the estimated caloric requirement for each participant to
maintain a stable weight.
Nicole Landa Cavallaro et al.
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to compare the effects of study diets. A threshold of
alphaB0.05 was the threshold for statistical significance.
Results
Five participants were enrolled into the study and all
completed both controlled diet interventions (Fig. 1).
All volunteers were healthy men, with an average age
(mean9SE) of 27.692.3 years and average BMI of 25.39
1.0 kg/m2. All participated in regular exercise at baseline
and consumed at least two meals prior to starting the study.
Nutritional characteristics of the native (baseline) diet
and study diets are shown in Table 2. The same informa-
tion is displayed, on a per individual basis, in Table 3.
Both the low and high BCAA content diet contained
more calories (total), a greater percentage of calories from
carbohydrate and a lower percentage of calories from
protein as compared with the native diets of the partici-
pants. The low and the high BCAA study diets did not
differ from each other in terms of total calories, or percent
of calories from protein, fat, or carbohydrate.
By design, the low BCAA and high BCAA diets differed
from the native diet and from each other in BCAA content
(Table 1). As compared with the native diet, the low BCAA
diet had lower amounts of valine (p0.006), leucine
(p0.005), and isoleucine (p0.007), and the high BCAA
diet had higher amounts of valine (pB0.0001), leucine
(pB0.0001), and isoleucine (pB0.0001). Consequently, the
amount of each BCAA was different in the low and high
BCAA diet (pB0.0001 for all).
During the low BCAA diet, participants consumed
90% of the study meals and supplements and consumed
less than one non-study meal. During the high BCAA
diet, participants consumed 97% of the study meals and
supplements and consumed less than one non-study
meal. Participants adhered to not more than one coffee
or tea per day and did not consume alcohol during both
diets. Each participant maintained baseline levels of
exercise during both study periods. Metabolic parameters
remain unchanged during study diets. Fasting glucose
and insulin at baseline were 8993.02 mg/dL and 6.391.2
mIU/mL, respectively, and there was no change in either
fasting glucose or insulin as a result of the low (p0.52
and p0.79, respectively) or high BCAA content inter-
vention (p0.51 and p0.29, respectively). Weight at
baseline was 81.495.2 kg and was slightly lower when
compared with the weight following either the low BCAA
intervention (80.795.2 kg, p0.04) or high BCAA
intervention (80.890.16, p0.16); weight was not dif-
ferent at the end of the low and high BCAA content
interventions (80.795.2 kg vs. 80.890.16 kg, p0.54).
Figure 2 shows fasting BCAA levels on the native, low
BCAA, and high BCAA diets across all participants.
Following the low BCAA diet, there was a numerical
decrease in fasting valine, leucine, and isoleucine from the
native diet levels, but none of these comparisons were
statistically significant. Following the high BCAA diet,
fasting levels of valine, leucine, and isoleucine did not
differ significantly from the native diet. The fasting levels
at the end of the low BCAA vs. the high BCAA
intervention were significantly lower for valine (p0.02)
and numerically lower for leucine (p0.16) and isoleucine
(p0.38). Thus, a consistent pattern of modest differ-
ences in fasting BCAA levels was observed between the
two study diets.
The fasting BCAA levels for each participant, sepa-
rately, are shown in Fig. 3. Following the low BCAA diet,
the largest numerical decreases from baseline in fasting
valine, leucine, and isoleucine were observed in Subjects
1 and 4; modest numerical decreases were observed
in Subject 5; and minimal decreases or increases were
observed in Subjects 2 and 3. Following the high BCAA
diet, the largest numerical increases from baseline in
fasting valine, leucine, and isoleucine were observed
in Subject 3; minimal decreases or increases were observed
in the other participants.
Subjects 1, 3, and 4 had the largest differences in fasting
valine, leucine, and isoleucine following the low and high
BCAA diets, and these differences followed the expected
pattern of higher levels following the high BCAA diet as
compared with the low BCAA diet. Subjects 2 and 5 had
smaller differences in the amino acids following the low
and high BCAA interventions, and these differences did
not always follow the expected pattern.
There were no adverse events during the study inter-
ventions. The participants rated the quality of the dietary
interventions relatively high (10-point scale; 0worst,
10best). For the low and high BCAA interventions,
respectively, taste of food was rated (mean [lowest
highest]) 8.8 (610) and 9.1 (710), and taste of supple-
ment was rated 5.5 (2.510) and 6.1 (110). Participants
estimated that they could adhere to the low BCAA diet
intervention for 5.2590.8 weeks and to the high BCAA
diet intervention for 6.7591.2 weeks.
Conclusions
In this pilot study, we tested whether a specific dietary
intervention, using differences in BCAA intake, alters fasting
BCAA levels independent of other factors. Participants
tolerated the diets, rated them favorably on qualitative
measures, and adhered closely to the prescribed interven-
tions. Fasting valine was lower and fasting leucine and
isoleucine trended lower after a low BCAA content diet
as compared with after a high BCAA content diet. Group
trends were for fasting valine, leucine, and isoleucine to
be lower after the low BCAA diet and higher after the
high BCAA diet as compared with levels on a native diet,
but these effects were not consistent across subjects.
While the nutritional intervention in this study had
modest effect, our findings suggest that interindividual
differences, not characterized in this study, may have a
Influence of branched chain amino acids on fasting levels
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more important role than dietary intake in determining
fasting levels of BCAAs. This result is consistent with
larger observational studies that have found no association
between BCAA intake, as assessed by dietary recall, and
fasting BCAA levels (6). Genome-wide association stu-
dies have found that genetic factors are responsible for
determining up to 20% of BCAA levels; clinical factors,
including age, sex, blood pressure, body mass index, and
the presence of specific medical conditions, are respon-
sible for an additional 30% of isoleucine and leucine
levels and an additional 20% of valine levels (10). Thus,
despite being essential amino acids, no more than 50% of
the levels of isoleucine or leucine and no more than 60%
of the levels of valine are influenced by diet alone.
Fasting levels of BCAAs are strongly influenced by
protein degradation (11) and uptake of BCAAs by muscle
(1218). In the post-absorptive state, BCAAs are released
from muscle and contribute to the fasting levels (19, 20).
Exercise influences BCAA turn-over in muscle (21), which
can be affected by amino acid intake (22, 23). Thus,
any effort to maximally change fasting BCAAs through
diet would likely also need to limit physical activity and
other contributors to muscle utilization and breakdown.
The absence of restriction on physical activity in this study
may also explain why the effects of a controlled diet on
circulating BCAAs were modest.
These results indicate that application of only a low or
high BCAA content nutritional intervention in the short
term without physical activity restriction is unlikely to
result in a consistent decrease or increase, respectively, in
circulating BCAAs from a native diet across individuals.
Furthermore, because participants indicated they could
adhere to either diet for less than 8 weeks, this approach
is unlikely to be effective for prevention or treatment of
chronic metabolic conditions.
However, our pilot study showed that modest differ-
ences in fasting BCAAs can be achieved in groups of
individuals by comparing levels after a low BCAA diet and
a high BCAA diet. The randomized, crossover design of
this study increases the likelihood that any observed group
differences were related to the intervention itself. While a
statistical separation in fasting valine levels on a low versus
high BCAA diet was achieved in this study with five
individuals, larger studies using our interventions could
achieve this separation for fasting leucine and isoleucine
as well. Assuming a similar effect size as observed in this
study, we would have 85% power to detect a significant
difference in fasting leucine and isoleucine levels with 16
or 47 subjects, respectively. A study of such size could use
the nutritional intervention from this study to explore
mechanisms linking fasting BCAAs to altered metabolism.
The nutritional intervention platform developed here may
be applied to other amino acids and nutrient metabolites.
Our approach is flexible, incorporates food and specific
supplements, and, because we used a metabolite profiling
platform that can quantify amino acid and non-amino acid
Table 2. Nutritional composition of native diets and the low and
high BCAA content interventions
Native diet Low BCAA diet High BCAA diet
Total calories (kcal) 2000.29341.5 2422.79172.8 2494.19183.5
% Carbohydrate 49.095.7 53.090.3 53.390.4
% Fat 31.194.7 30.890.6 31.190.7
% Protein 19.691.9 16.390.3 15.790.4
Valine (g) 5.191.0 1.590.1 14.090.6
Leucine (g) 7.791.5 2.190.2 27.191.0
Isoleucine (g) 4.590.9 1.290.1 13.890.5
The mean9standard errors for measures of the native diet and for the
low and high BCAA content interventions are shown. Nutrient profile
of the native diet was derived from a 4-day food log. The low and high
BCAA interventions ware based on meal plans and food consumed.
Table 3. Baseline and intervention dietary characteristics for each study subject
Participant S1 Participant S2 Participant S3 Participant S4 Participant S5
Native Low High Native Low High Native Low High Native Low High Native Low High
Total calories 1062 1781 1871 2168 2398 2405 2303 2549 2589 1452 2800 3000 3016 2586 2605
% Carbohydrate 60.1 53.9 54.6 41.1 52.1 52 39.9 52.7 52.8 65.6 52.6 53.3 38.2 53.5 53.7
% Fat 20.2 28.7 28.7 37.9 31.4 32 33 31.3 31.5 20.6 32.1 32.5 43.9 30.5 30.8
% Protein 19.7 17.4 16.8 20.9 16.6 16 25.5 16.1 15.7 13.8 15.3 14.2 18 16.1 15.6
Valine (g) 2.6 1.08 12 6 1.4 13.8 7.2 1.6 14.6 2.8 1.8 15.2 6.7 1.6 14.6
Leucine (g) 4.2 1.5 23.4 8.7 1.9 26.6 11.2 2.2 28.1 4.1 2.5 29.3 10.2 2.3 28.1
Isoleucine (g) 2.3 0.9 11.9 5.3 1.1 13.5 6.7 1.3 14.3 2.3 1.5 14.9 5.7 1.4 14.3
% Study diet consumed 89% 93% 100% 98% 98% 99% 100% 100% 98% 100%
The measures of the native diet and for the low and high BCAA interventions for are shown for each participant. Information from the native diet was
based on self-report from a 4-day food record (with assisted review by research nutritionist) analyzed in 2013 data base version of Nutrition Data
System for Research (NDSR). Information from the low and high BCAA interventions is based on the consumption of actual amounts of provided meals
based on Pronutra version 3.4.0 analysis.
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metabolites simultaneously, permits measurement of a
broad range of dietary hypotheses. Whether fasting levels
of other amino acids or nutrient metabolites with possible
metabolic effects can be more easily modulated through
dietary intake should be tested in different experiments.
Thus, our platform offers a structured method of testing
the influence of controlled dietary manipulation on fasting
levels of specific nutrient metabolites and their implication
on different conditions.
Strengths of this study include a design of a novel
controlled dietary intervention, crossover application in
random order to the low and high BCAA diets so that each
subject served as his own control, high adherence to study
diet, and measurement of BCAA levels in the fasted state
before and after each intervention. Still, we acknowledge
limitations to our study. We studied healthy subjects
and for only 4 days on each intervention. This pilot study
provided data to demonstrate that our method could be
applied to other populations. It is possible that dietary
manipulation of BCAA would be more effective in obese
or insulin resistant individuals, who are known to have
dysregulation of BCAA metabolism (1, 3), or would be
more effectively in modulating BCAAs over long periods
of a controlled diet. Second, we measured BCAAs only in
the fasted state and only from venous blood. It is possible
that, while on low or high BCAA content diets, circulating
levels are more divergent in the post-prandial state or in
other biological compartments, such as muscle. We used
fasting values from venous samples as they are the ones
previously identified as metabolic risk factors in obesity
(1, 3), pre-diabetic states (4), and incident T2D (4, 6).
Third, we did not restrict or control the amount of
physical activity of the research participants. While par-
ticipants were instructed to maintain baseline levels of
physical activity throughout the study, differences in
muscle turnover and metabolism may have influenced
our results. While the goal of this study was to assess
the influence of dietary intake alone on fasting BCAA
levels, further studies using a dietary approach should
also control physical activity to have maximal influence on
fasting BCAA levels. Finally, all BCAAs were manipu-
lated in the same diet. It is possible that a low or high
isoleucine content diet, for example, would have been
Fig. 2. Fasting BCAAs levels following native diet and low
and high BCAA content interventions. Shown are mean9
standard error for fasting valine, leucine, and isoleucine on
the native diet (dark gray bar) and following the low BCAA
(light gray bar) and high BCAA (striped bar) interventions.
Fasting BCAAs are presented in arbitrary units, representing
area under the curve as measured on the mass spectrometer.
Fig. 3. Fasting BCAAs levels for each participant following native diet and low and high BCAA content interventions. Shown
are mean9standard error for fasting valine, leucine, and isoleucine on the native diet (dark gray bar) and following the low
BCAA (light gray bar) and high BCAA (striped bar) interventions. Fasting BCAAs are presented in arbitrary units, representing
area under the curve as measured on the mass spectrometer. Each number title corresponds to one of the five study participants.
Influence of branched chain amino acids on fasting levels
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more effective at altering isoleucine levels than the one
that manipulated all three BCAAs. Future studies could
examine the feasibility of altering only one amino acid,
particularly if it is of higher interest than others.
In conclusion, we constructed a novel nutritional
intervention to test whether short-term intake of a con-
trolled diet could alter circulating levels of BCAAs in this
pilot study. The intervention was more effective at provid-
ing a modest difference in BCAA levels following the
low and high BCAA diets than in consistently lowering
or raising circulating BCAAs from the native diet. Future
studies can utilize the interventional construct developed
here, along with physical activity restriction, to test the
effect of BCAA or other amino acid manipulation under
different experimental settings.
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